Zealand Pharma and Generate Biomedicines sign obesity drug deal worth up to $1.2 billion

Danish drugmaker Zealand Pharma and U.S. biotechnology company Generate Biomedicines said on October 13, 2026 that they will partner to develop protein-based treatments for obesity and other metabolic diseases designed with artificial intelligence, in a deal that could be worth up to nearly $1.2 billion in milestone payments ^[1][3].

Under the terms, Generate will receive $30 million upfront and up to $35 million in early preclinical milestones, and is eligible for total milestone payments of nearly $1.2 billion tied to development, regulatory and commercial achievements ^[1][2][3]. Zealand also agreed to pay tiered royalties on worldwide net sales of any products resulting from the agreement ^[2]. The pact initially covers two experimental drug programs, with an option to add a third, according to a document reviewed by Bloomberg ^[3]. Generate's shares were up about 5% in extended trading after the announcement ^[1].

Generate will lead research through candidate selection using its AI-driven technology, while Zealand will handle clinical development, regulatory submissions and worldwide commercialization ^[1][2]. The collaboration targets multispecific protein therapies — medicines designed to act on more than one biological target at a time. Zealand said those treatments could target several disease pathways linked to obesity within a single medicine, an approach drugmakers are increasingly exploring ^[1]. Zealand Chief Scientific Officer Utpal Singh said the collaboration "expands our toolbox to include proteins, complementing our existing small-molecule and peptide capabilities" ^[2].

Zealand has traditionally focused on peptide-based medicines and is jointly developing the obesity drug petrelintide with Roche as part of an agreement signed last year worth up to $5.3 billion ^[1]. Its obesity pipeline centers on a Roche-partnered amylin analog and a Boehringer Ingelheim-partnered glucagon/GLP-1 receptor dual agonist; both are in phase 3 ^[2]. In December, the company moved into small molecules through a partnership with OTR Therapeutics ^[2]. Generate, backed by Flagship Pioneering, went public earlier in 2026 ^[1]. Its internal pipeline focuses on immunology, inflammation and oncology, and its most advanced asset is GB-0895, an anti-TSLP monoclonal antibody in phase 3 for severe asthma ^[2]. Amgen and Novartis previously signed deals with Generate in 2022 and 2024 to develop protein therapeutics ^[2].

Earlier in October, Zealand reported mid-stage results showing that treatment helped overweight and obese patients with type 2 diabetes lose up to 9.2% of their body weight ^[1]. Accounts of that data differed: one report described the results as positive ^[1], while another said the weight-loss and blood-sugar data on the Roche-partnered asset disappointed analysts, and that phase 3 data on the Boehringer-partnered program sent Zealand's stock price down at the start of October ^[2].

Why it matters for patients

The programs covered by this deal are at the research stage. No human testing of any candidate from the Zealand-Generate collaboration has been reported, and the companies have not disclosed when a candidate might be selected or when clinical trials could begin. Most of the nearly $1.2 billion is not guaranteed; it depends on programs reaching research, development, regulatory and commercial milestones ^[1][2][3].

The medicines involved are multispecific proteins, a different category from the current GLP-1 obesity drugs sold by Novo Nordisk and Eli Lilly, which the deal's backers are aiming to move beyond ^[1]. Whether multispecific proteins produce better weight loss, fewer side effects or more convenient dosing is not known; companies across the obesity market are testing approaches aimed at improving effectiveness, convenience or side-effect profiles ^[1]. Any product from this partnership would be years away from reaching patients if it succeeds at all.

Nothing in the announcement concerns approved medicines; it covers experimental compounds still in research, and the deal does not change what is available or covered today.

What happens next

Generate is expected to design and develop candidates through lead-candidate selection, then hand the programs to Zealand for clinical development ^[2]. No dates for candidate selection, trial starts or regulatory filings have been disclosed. Zealand holds an option to add a third program to the agreement ^[3]. Milestone payments would be triggered as the programs advance ^[1][2][3].